ArticleImmunity2020
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4
Open access · hybridAbstract read
In one paragraph
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers.
0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 219 citations in OpenAlex.
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- Targeting BCL9/BCL9L enhances CD4Acta pharmacologica Sinica · 2026Article
- Assessment of Tfh Cells and Related Molecules in CML-CP Patients With Different Molecular Responses.International journal of laboratory hematology · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments.The Journal of experimental medicine · 2026Article
- Modular Vaccine Robots for Spatiotemporal Programming of the CD4Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3.Scientific reports · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- Regulatory T cells in axial spondyloarthritis.Communications biology · 2026Review
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- UC-MSCs-derived exosomal circFOXP1 alleviates allergic rhinitis through EZH2/EGR1/Blimp-1 axis.Respiratory research · 2026Article
- Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence.Current HIV/AIDS reports · 2026Review
- CD4Cancer biology & medicine · 2026Review
- Article
- Cancer Immunomodulatory Effect ofCells · 2026Article
- Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy?Journal for immunotherapy of cancer · 2025Review
- Salmonella-superspreader hosts require gut regulatory T cells to maintain a disease-tolerant state.The Journal of experimental medicine · 2025Article
- PRDM15 regulates differentiation and proliferation of hematopoietic stem cells.Research square · 2025Article
- The transcription factor Blimp-1 is suppressed by SLAMF1 and drives Treg cell-mediated immune evasion in non-small cell lung cancer.BJC reports · 2025Article
- Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.The Journal of clinical investigation · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 3 countries.
Anna ŚledzińskaCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Maria Vila de MuchaCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Regulatory Genomics Research Group, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
Katharina BergerhoffCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Alastair HotblackResearch Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Dafne Franz DemaneCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Ehsan GhoraniCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Ayse U AkarcaDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Maria A V MarzoliniCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Isabelle SolomonCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Frederick Arce VargasCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Martin PuleResearch Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK.
Masahiro OnoFaculty of Natural Sciences, Department of Life Sciences, Imperial College London, London SW7 2BB, UK.
Benedict SeddonInstitute of Immunity and Transplantation, Department of Immunology, Royal Free Hospital, London NW3 2PF, UK.
George KassiotisRetroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Charlotte E AriyanMemorial Sloan Kettering Center, 1275 York Avenue, New York, NY 10065, USA.
Thomas KornDepartment of Experimental Neuroimmunology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany.
Teresa MarafiotiDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Graham M LordFaculty of Biology, Medicine and Health, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK.
Hans StaussInstitute of Immunity and Transplantation, Department of Immunology, Royal Free Hospital, London NW3 2PF, UK.
Richard G JennerRegulatory Genomics Research Group, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
Karl S PeggsCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK. Electronic address: k.peggs@ucl.ac.uk.
Sergio A QuezadaCancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK; Research Department of Haematology, University College London, Cancer Institute, London WC1E 6DD, UK. Electronic address: s.quezada@ucl.ac.uk.
London Cancer · GBUniversity College London · GBThe Royal Free Hospital · GBImperial College London · GBMemorial Sloan Kettering Cancer Center · USTechnical University of Munich · DEThe Francis Crick Institute · GBUniversity of Manchester · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCancer Research UK 12100Cancer Research UK 16463Cancer Research UK 20265Cancer Research UK 20764Cancer Research UK 22246Cancer Research UK 536392/170773Cancer Research UK C33499/A20265Cancer Research UK C36463/A20764Cancer Research UK C36463/A22246Cancer Research UK C416/A18088Department of Health 167097Medical Research Council MR/M003493/1Medical Research Council MR/P011225/1Medical Research Council MR/R001413/1NCI NIH HHS P30 CA008748
Abstract
In addition to helper and regulatory potential, CD4
Indexed as
Adoptive TransferAnimalsCell Line, TumorGranzymesHumansInterferon-gammaInterleukin-2MiceMice, Inbred C57BLMice, KnockoutNeoplasmsPositive Regulatory Domain I-Binding Factor 1T-bet Transcription FactorT-Box Domain ProteinsT-Lymphocytes, RegulatoryTumor MicroenvironmentGranzymesGzmb protein, mouseIFNG protein, mouseInterferon-gammaInterleukin-2Positive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseT-bet Transcription FactorT-Box Domain Proteinsanti-CTLA-4Blimp-1CD4-mediated anti-tumor responsecytotoxic CD4(+) T cellsIL-2regulatory T cellsT-betTreg depletion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.